Literature DB >> 10868851

Cardiovascular risk profile in individuals with borderline glycemia: the effect of the 1997 American Diabetes Association diagnostic criteria and the 1998 World Health Organization Provisional Report.

S C Lim1, E S Tai, B Y Tan, S K Chew, C E Tan.   

Abstract

OBJECTIVE: In 1997, the American Diabetes Association (ADA) recommended a new diagnostic category, impaired fasting glucose (IFG), to describe individuals with borderline glucose tolerance. On the other hand, the World Health Organization (WHO) suggested retaining the category of impaired glucose tolerance (IGT). We studied the prevalence of IFG and IGT in a multiethnic society and compared the cardiovascular risk profiles of subjects with IFG, IGT, or both IFG and IGT. RESEARCH DESIGN AND METHODS: A total of 3,568 subjects were examined from the 1992 National Health Survey of Singapore, which involved a combination of disproportionately stratified sampling and systematic sampling. Anthropometric, blood pressure, insulin, lipid profile, and uric acid measurements were taken, and a standard 75-g oral glucose tolerance test was performed after a 10-h overnight fast.
RESULTS: The prevalence rates of IFG only, IGT only, and both IFT and IGT were 3.45, 10.2, and 3.4%, respectively. The degree of agreement (kappa) between the two diagnostic criteria (the ADA IFG and the WHO IGT) was only 0.25. A fasting glucose level of 5.5 mmol/l was the optimal cutoff for predicting a 2-h postload glucose level of > or =7.8 mmol/l. The following cardiovascular risk factors were higher in subjects with both IFG and IGT compared with those with either IFG or IGT alone: systolic blood pressure (131 +/- 20 vs. 125 +/- 21 and 125 +/- 19 mmHg, respectively; P < 0.05 and P < 0.001, respectively); diastolic blood pressure (77 +/- 12 vs. 73 +/- 12 and 74 +/- 12 mmHg, respectively; P < 0.05); BMI (26.2 +/- 4.2 vs. 24.4 +/- 4.0 and 24.6 +/- 4.4 kg/m2, respectively; P < 0.01 and P < 0.001, respectively); waist circumference (84.1 +/- 10.3 vs. 79.3 +/- 10.7 and 79.3 +/- 10.6 cm, respectively; P < 0.001); waist-to-hip ratio (0.84 +/- 0.08 vs. 0.82 +/- 0.09 and 0.81 +/- 0.08, respectively; P < 0.05 and P < 0.001, respectively); fasting insulin (12.1 +/- 9.7 vs. 9.2 +/- 5.3 and 9.9 +/- 7.7 mU/l; P < 0.01); insulin resistance (by homeostasis model assessment [HOMA]) (3.41 +/- 2.77 vs. 2.58 +/- 1.50 and 2.43 +/- 1.83, respectively; P < 0.01 and P < 0.001, respectively); total cholesterol (5.81 +/- 1.1 vs. 5.51 +/- 1.1 and 5.53 +/- 1.1 mmol/l, respectively; P < 0.05) and apolipoprotein(B) [apo(B)] (1.5 +/- 0.38 vs. 1.40 +/- 0.34 and 1.39 +/- 0.35 mmol/l, respectively; P < 0.01). The pattern of difference remained significant only for fasting insulin, insulin resistance (HOMA), and apo(B) (borderline) after adjustment for age, sex, and ethnic differences.
CONCLUSIONS: Obvious discordance was evident in the classification of glycemic status when applying the criteria proposed by the ADA (IFG) or WHO (IGT) in a multiethnic society like Singapore. However, subjects with either IFG or IGT had similar cardiovascular risk profiles. Therefore, both criteria identified individuals at high risk for cardiovascular disease. Individuals with both IFG and IGT had a greater incidence of the cardiovascular dysmetabolic syndrome.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10868851     DOI: 10.2337/diacare.23.3.278

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  9 in total

Review 1.  Prediabetes and cardiovascular risk in hypertensive patients.

Authors:  Julian Segura; Cecilia Roldán; Jose A García-Donaire; Luis M Ruilope
Journal:  Curr Hypertens Rep       Date:  2006-05       Impact factor: 5.369

Review 2.  Change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance.

Authors:  Maryna Popp Switzer; Sherif Elhanafi; Zinnia T San Juan
Journal:  Curr Cardiol Rep       Date:  2015-03       Impact factor: 2.931

3.  Metabolic syndrome as a risk factor for gallstone disease.

Authors:  Nahum Méndez-Sánchez; Norberto C Chavez-Tapia; Daniel Motola-Kuba; Karla Sanchez-Lara; Guadalupe Ponciano-Rodríguez; Héctor Baptista; Martha H Ramos; Misael Uribe
Journal:  World J Gastroenterol       Date:  2005-03-21       Impact factor: 5.742

4.  Association among C-reactive protein, Fatty liver disease, and cardiovascular risk.

Authors:  Javier Lizardi-Cervera; Norberto C Chavez-Tapia; Oliver Pérez-Bautista; Martha H Ramos; Misael Uribe
Journal:  Dig Dis Sci       Date:  2007-04-10       Impact factor: 3.199

5.  Lucica MI urinary myoinositol kit: a new diagnostic test for diabetes mellitus and glucose intolerance.

Authors:  Masaru Yamakoshi; Shoji Kawazu
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

6.  Postprandial Differences in the Amino Acid and Biogenic Amines Profiles of Impaired Fasting Glucose Individuals after Intake of Highland Barley.

Authors:  Liyan Liu; Xinyang Wang; Ying Li; Changhao Sun
Journal:  Nutrients       Date:  2015-07-09       Impact factor: 5.717

7.  Prevalence of diabetes mellitus in the elderly of Namwon County, South Korea.

Authors:  Sang Guk Kim; Seung Won Yang; An Soo Jang; Jeong Pyeong Seo; Sang Woo Han; Chung Ho Yeom; Yong Chul Kim; Sung Hee Oh; Jung Seok Kim; Hae Sung Nam; Dong Jin Chung; Min Young Chung
Journal:  Korean J Intern Med       Date:  2002-09       Impact factor: 2.884

8.  An evaluation of glucose tolerance in essential hypertension.

Authors:  Armagan Tugrul; Sibel Guldiken; Betul Ugur-Altun; Ender Arikan
Journal:  Yonsei Med J       Date:  2009-04-30       Impact factor: 2.759

9.  Cardiometabolic Risk Profiles in Patients With Impaired Fasting Glucose and/or Hemoglobin A1c 5.7% to 6.4%: Evidence for a Gradient According to Diagnostic Criteria: The PREDAPS Study.

Authors:  Carolina Giráldez-García; F Javier Sangrós; Alicia Díaz-Redondo; Josep Franch-Nadal; Rosario Serrano; Javier Díez; Pilar Buil-Cosiales; F Javier García-Soidán; Sara Artola; Patxi Ezkurra; Lourdes Carrillo; J Manuel Millaruelo; Mateu Seguí; Juan Martínez-Candela; Pedro Muñoz; Albert Goday; Enrique Regidor
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.889

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.